CAS NO: | 2578876-75-0 |
生物活性 | KRAS inhibitor-10 selectively and effectively inhibitRASproteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used forcancerresearch, such as pancreaticcancer, breastcancer, multiple myeloma, leukemia and lungcancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1[1]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | KRAS inhibitor-10 (0.1-50 μΜ; 72 hours) has antiproliferative effects in KRas mutant tumor cells, KRAS inhibitor-10 is against A549 (lung carcinoma cell line bearing KRasG12Soncogenic mutation), H358 (non-small cell lung cancer line bearing KRasG12Concogenic mutation), PANC-1 (epithelioid carcinoma of the pancreas cell line bearing KRasG12Doncogenic mutation) and RPMI (myeloma cell line bearing KRasG12Aoncogenic mutation) cell proliferation with IC50values of 0.2 μM, 0.2 μM, 0.1 μM and 0.8 μM, respectively[1].KRAS inhibitor-10 (0-1 μM, 7 days) is against cell viability in a 3D CellTiter-GloTM cell viability assay for NIH-H358 cell, the IC50value is 0.413 μM[1]. | ||||||||||||||||
体内研究 (In Vivo) | KRAS inhibitor-10 (oral administration; 20 mg/kg; BID; 27 days) is safe and tolerate for the bearing mice. KRAS inhibitor-10 demonstrates significant oral anti-tumor activities in vivo. And the tumor growth inhibition (TGI) value is 48.22% for KRAS inhibitor-10[1].
| ||||||||||||||||
分子量 | 519.63 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C30H37N3O5 | ||||||||||||||||
CAS 号 | 2578876-75-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(192.44 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |